ESSA Pharma Inc
EPIX1.880USD
0.000
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
83.45MValor de mercado
PerdaP/L TTM
Mais detalhes de ESSA Pharma Inc Empresa
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Informações da empresa
Código da empresaEPIX
Nome da EmpresaESSA Pharma Inc
Data de listagemFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Número de funcionários35
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 22
Endereço999 West Broadway, Suite 720
CidadeVANCOUVER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalV5Z 1K5
Telefone17783310962
Sitehttps://www.essapharma.com/
Código da empresaEPIX
Data de listagemFeb 22, 2021
CEODr. David Ross Parkinson, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Dr. David Ross Parkinson, M.D.
Dr. David Ross Parkinson, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Alex Martin
Mr. Alex Martin
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Richard M. Glickman, LL.D.
Dr. Richard M. Glickman, LL.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
51.70K
-14.06%
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
33.59K
+0.75%
Mr. Scott Requadt
Mr. Scott Requadt
Independent Director
Independent Director
30.00K
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.78K
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
5.12K
--
Ms. Marella Thorell
Ms. Marella Thorell
Independent Director
Independent Director
2.88K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Investidores
Investidores
Proporção
BVF Partners L.P.
19.71%
Soleus Capital Management, L.P.
9.83%
Tang Capital Management, LLC
9.69%
BML Capital Management LLC
9.51%
Morgan Stanley & Co. LLC
9.46%
Other
41.80%
Tipos de investidores
Investidores
Proporção
Hedge Fund
46.19%
Investment Advisor
13.36%
Research Firm
11.99%
Corporation
3.77%
Investment Advisor/Hedge Fund
2.45%
Individual Investor
2.24%
Venture Capital
0.05%
Other
19.93%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
91
33.44M
75.34%
-17.34M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
2023Q1
185
36.21M
82.14%
-19.98M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BVF Partners L.P.
8.75M
19.71%
--
--
Apr 09, 2025
Soleus Capital Management, L.P.
2.26M
5.1%
--
--
Apr 23, 2025
Tang Capital Management, LLC
4.30M
9.69%
--
--
Mar 31, 2025
BML Capital Management LLC
4.22M
9.51%
--
--
Apr 24, 2025
Morgan Stanley & Co. LLC
4.20M
9.46%
+10.76K
+0.26%
Mar 31, 2025
Opaleye Management Inc.
2.21M
4.98%
--
--
Mar 31, 2025
Pfizer Inc
1.68M
3.77%
--
--
Mar 31, 2025
Altium Capital Management LP
1.05M
2.37%
-377.63K
-26.44%
Mar 31, 2025
Berger (Franklin Milan)
784.40K
1.77%
--
--
Jan 08, 2025
BofA Global Research (US)
698.27K
1.57%
-114.04K
-14.04%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
